Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
Phase of Trial: Phase IV
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BLAST
- 06 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 06 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated